-+ 0.00%
-+ 0.00%
-+ 0.00%
Johnson & Johnson to Present MEMBRANE Trial Analysis on Cognitive Outcomes After Brain Bleed Treatment
Share
Listen to the news
Johnson & Johnson to Present MEMBRANE Trial Analysis on Cognitive Outcomes After Brain Bleed Treatment
  • Johnson & Johnson will present 13 neurovascular research abstracts, including four podium presentations, at SVIN 2026 in Las Vegas.
  • MEMBRANE trial analyses will examine cognitive outcomes, anesthesia approaches and healthcare resource use following embolization for chronic subdural hematoma.
  • Cognitive findings will be presented November 19; 12-month results for treatment with TRUFILL n-BCA are scheduled for November 20.
  • The EXCELLENT registry presentation on November 20 will examine ischemic stroke treatment outcomes and clot characteristics in 2,000 patients across three continents.
  • That prospective registry included first-line use of CEREGLIDE 71 and EMBOTRAP devices.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending